BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who
have refractory non-Hodgkin's lymphoma.